Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyethylene glycol 600 (PEG 600) is a polyether compound with a mean molecular weight of 600 Daltons, commonly used in clinical research as a molecular probe to assess intestinal mucosal barrier function. As a metabolically inert substance that is not normally absorbed by a healthy colonic mucosa, its presence in urine following rectal or oral administration serves as a marker for increased intestinal permeability. In patients with inflammatory bowel disease, such as ulcerative colitis, the absorption of PEG 600 is significantly elevated during active inflammation, providing a quantitative measure that correlates with endoscopic and histological disease activity. While not a therapeutic agent, PEG 600 is a valuable diagnostic tool for investigating the pathogenesis and systemic manifestations of intestinal barrier defects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol 600.